Such antibodies may be effectors, or their detection may have utility as a correlate or surrogate of vaccine-induced cross-protection [21]. The development of potential next generation vaccines to improve the breadth of genotype coverage [1] and [22]

is based upon two approaches: improving the immunogenicity of a conserved region of the minor capsid protein (L2) to generate broadly neutralizing antibodies [23], and using a multivalent L1 VLP-based vaccine that induces type-specific antibodies against a wider array of HPV genotypes (HPV6, HPV11, HPV16, HPV18, HPV31, HPV33, HPV45, HPV52, HPV58; V503, Merck Research Laboratories). The latter approach is the most advanced www.selleckchem.com/products/RO4929097.html and early clinical trial data show promising immunogenicity and efficacy profiles [24], whereas L2-based candidate vaccines are currently in pre-clinical development [23]. Reduced dosing schedules for the current HPV vaccines are also being investigated with data suggesting non-inferiority of type-specific antibody responses, although there is an impact on the development of cross-neutralizing JQ1 ic50 antibodies [10], [25], [26] and [27]. Early pre-clinical immunogenicity [28], [29] and [30] and MAb reactivity [17] data suggest a degree of inter-genotype antigenic similarity within the Alpha-7 and Alpha-9 species

groups. The extent of this antibody cross-reactivity is unclear as only a limited number of immunogens and target antigens have been used. Some of these

data have been generated using L1-based targets [28], rather than pseudovirus targets bearing both the L1 and L2 proteins, with both proteins being necessary for efficient infectivity and the appropriate presentation of L1 conformational epitopes [23], [31] and [32]. We carried out a comprehensive pre-clinical evaluation of the immunogenicity of L1 VLP derived from multiple HPV genotypes within the Alpha-7 and Alpha-9 species groups and used L1L2 pseudoviruses, representing these same genotypes, as the target antigens in neutralization assays. Such data should improve our understanding of the antigenic Ketanserin diversity of the L1 protein per se and may inform the design of a next generation vaccine formulation that encompasses a limited number of antigens based upon empirical data. Cervarix® was obtained through the National Vaccine Evaluation Consortium, UK. L1 VLP representing Alpha-7 and Alpha-9 HPV genotypes and control Bovine Papillomavirus (BPV) were expressed using the Bac-to-Bac® Baculovirus System (Life Technologies), as previously described [33] and [34], wherein the L1 genes shared 100% amino acid sequence identity with the L1 genes of the pseudovirus clones [20] used for the neutralization assay (see inhibitors Section 2.3). Five week old female BALB/c mice were immunized with saline (naïve) or 1/10th (2 μg each HPV16 and HPV18 VLP) the human dose equivalent of Cervarix®[35] by the intramuscular (IM) or sub-cutaneous (SC) routes.